Misplaced Pages

Lentinan: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 09:50, 5 November 2023 editArtoria2e5 (talk | contribs)Extended confirmed users, IP block exemptions34,635 edits delete "mycelium", we eating the caps here← Previous edit Revision as of 18:39, 22 November 2023 edit undoBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,946 edits consistent citation formattingNext edit →
Line 51: Line 51:
==Research== ==Research==
===Preclinical studies=== ===Preclinical studies===
An '']'' experiment showed lentinan stimulated production of white blood cells in the human cell line ].<ref name="pmid = 10190187 ">{{cite journal | vauthors = Sia GM, Candlish JK | title = Effects of shiitake (Lentinus edodes) extract on human neutrophils and the U937 monocytic cell line | journal = Phytotherapy Research | volume = 13 | issue = 2 | pages = 133–137 | date = March 1999 | pmid = 10190187 | doi = 10.1002/(SICI)1099-1573(199903)13:2<133::AID-PTR398>3.0.CO;2-O | doi-access = free }}</ref> Lentinan is thought to be inactive in humans when given orally and is therefore administered intravenously. The authors of an '']'' study of lentinan suggested that the compound may be active when administered orally in mice.<ref name="pmid = 12470439">{{cite journal | vauthors = Ng ML, Yap AT | title = Inhibition of human colon carcinoma development by lentinan from shiitake mushrooms (Lentinus edodes) | journal = Journal of Alternative and Complementary Medicine | volume = 8 | issue = 5 | pages = 581–589 | date = October 2002 | pmid = 12470439 | doi = 10.1089/107555302320825093 }}</ref>
An '']'' experiment showed lentinan stimulated production of white blood cells in the human cell line ].<ref name="pmid = 10190187 ">{{Cite journal
|author1=Sia GM |author2=Candlish JK | title = Effects of shiitake (''Lentinus edodes'') extract on human neutrophils and the U937 monocytic cell line
| journal = Phytotherapy Research
| volume = 13
| issue = 2
| pages = 133–7
| date=Mar 1999
| doi = 10.1002/(SICI)1099-1573(199903)13:2<133::AID-PTR398>3.0.CO;2-O
| pmid = 10190187
| doi-access = free
}}</ref> Lentinan is thought to be inactive in humans when given orally and is therefore administered intravenously. The authors of an '']'' study of lentinan suggested that the compound may be active when administered orally in mice.<ref name="pmid = 12470439">{{Cite journal
|author1=Ng ML |author2=Yap AT | title = Inhibition of human colon carcinoma development by lentinan from shiitake mushrooms (''Lentinus edodes'')
| journal = Journal of Alternative and Complementary Medicine
| volume = 8
| issue = 5
| pages = 581–9
| location = National University of Singapore
| date=Oct 2002
| doi = 10.1089/107555302320825093
| pmid = 12470439
}}</ref>


===Human clinical trials=== ===Human clinical trials===
⚫ Lentinan has been the subject of a limited number of clinical studies in cancer patients in Japan;<ref name="pmid = 18670743">{{cite journal | vauthors = Yang P, Liang M, Zhang Y, Shen B | title = Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC | journal = Advances in Therapy | volume = 25 | issue = 8 | pages = 787–794 | date = August 2008 | pmid = 18670743 | doi = 10.1007/s12325-008-0079-x | s2cid = 33140754 | doi-access = free }}</ref><ref name="pmid = 16897983">{{cite journal | vauthors = Nimura H, Mitsumori N, Takahashi N, Kashimura H, Takayama S, Kashiwagi H, Yanaga K | title = | language = ja | journal = Gan to Kagaku Ryoho. Cancer & Chemotherapy | volume = 33 Suppl 1 | issue = 1 | pages = 106–109 | date = June 2006 | pmid = 16897983 }}</ref><ref name="pmid = 10522061">{{cite journal | vauthors = Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K | title = A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group | journal = Hepato-Gastroenterology | volume = 46 | issue = 28 | pages = 2662–2668 | year = 1999 | pmid = 10522061 }}</ref><ref name="pmid19596954">{{cite journal | vauthors = Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J | title = Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer | journal = Anticancer Research | volume = 29 | issue = 7 | pages = 2739–2745 | date = July 2009 | pmid = 19596954 }}</ref><ref name="pmid19596936">{{cite journal | vauthors = Hazama S, Watanabe S, Ohashi M, Yagi M, Suzuki M, Matsuda K, Yamamoto T, Suga Y, Suga T, Nakazawa S, Oka M | display-authors = 6 | title = Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer | journal = Anticancer Research | volume = 29 | issue = 7 | pages = 2611–2617 | date = July 2009 | pmid = 19596936 | url = http://ar.iiarjournals.org/content/29/7/2611.full }}</ref><ref name="pmid19579640">{{cite journal | vauthors = Kataoka H, Shimura T, Mizoshita T, Kubota E, Mori Y, Mizushima T, Wada T, Ogasawara N, Tanida S, Sasaki M, Togawa S, Sano H, Hirata Y, Ikai M, Mochizuki H, Seno K, Itoh S, Kawai T, Joh T | display-authors = 6 | title = Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life | journal = Hepato-Gastroenterology | volume = 56 | issue = 90 | pages = 547–550 | year = 2009 | pmid = 19579640 }}</ref><ref name="pmid19579616">{{cite journal | vauthors = Isoda N, Eguchi Y, Nukaya H, Hosho K, Suga Y, Suga T, Nakazawa S, Sugano K | display-authors = 6 | title = Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma | journal = Hepato-Gastroenterology | volume = 56 | issue = 90 | pages = 437–441 | year = 2009 | pmid = 19579616 }}</ref><ref name="pmid19453066">{{cite journal | vauthors = Shimizu K, Watanabe S, Watanabe S, Matsuda K, Suga T, Nakazawa S, Shiratori K | title = Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer | journal = Hepato-Gastroenterology | volume = 56 | issue = 89 | pages = 240–244 | year = 2009 | pmid = 19453066 }}</ref> however, evidence of ] is lacking.<ref name="webmd">{{cite web|title=Lentinan|url=http://www.webmd.com/vitamins-supplements/ingredientmono-763-lentinan.aspx?activeingredientid=763&activeingredientname=lentinan|publisher=]|access-date=June 10, 2017}}</ref><ref name="MSKCC">{{cite web|title=Lentinan|url=https://www.mskcc.org/cancer-care/integrative-medicine/herbs/lentinan|publisher=]|access-date=June 10, 2017}}</ref>
Lentinan has been the subject of a limited number of clinical studies in cancer patients in Japan;<ref name="pmid = 18670743">{{Cite journal
|author1=Yang P |author2=Liang M |author3=Zhang Y |author4=Shen B | title = Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC
| journal = Advances in Therapy
| volume = 25
| issue = 8
| pages = 787–94
| date=Aug 2008
| doi = 10.1007/s12325-008-0079-x
| pmid = 18670743
|s2cid=33140754 | doi-access =free
}}</ref><ref name="pmid = 16897983">{{Cite journal
| author1 = Nimura H | author2 = Mitsumori N | author3 = Takahashi N |display-authors=etal
| title =
| journal = Gan to Kagaku Ryoho
| volume = 33
| issue = 1
| pages = 106–9
| date=Jun 2006
| pmid = 16897983
| language = ja
}}</ref><ref name="pmid = 10522061">{{Cite journal
|author1=Nakano H |author2=Namatame K |author3=Nemoto H |author4=Motohashi H |author5=Nishiyama K |author6=Kumada K. | title = A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.
| journal = Hepatogastroenterology
| volume = 46
| issue = 28
| pages = 2662–8
| year = 1999
| pmid = 10522061
⚫ }}</ref><ref name="pmid19596954">{{cite journal |vauthors=Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J |title=Individual Patient Based Meta-analysis of Lentinan for Unresectable/Recurrent Gastric Cancer |journal=Anticancer Research |volume=29 |issue=7 |pages=2739–45 |date=July 2009 |pmid=19596954 }}</ref><ref name="pmid19596936">{{cite journal |vauthors=Hazama S, Watanabe S, Ohashi M, etal |title=Efficacy of Orally Administered Superfine Dispersed Lentinan (β-1,3-Glucan) for the Treatment of Advanced Colorectal Cancer |journal=Anticancer Research |volume=29 |issue=7 |pages=2611–2617 |date=July 2009 |pmid=19596936 |url=http://ar.iiarjournals.org/content/29/7/2611.full}}</ref><ref name="pmid19579640">{{cite journal |vauthors=Kataoka H, Shimura T, Mizoshita T, etal |title=Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life |journal=Hepatogastroenterology |volume=56 |issue=90 |pages=547–50 |year=2009 |pmid=19579640 }}</ref><ref name="pmid19579616">{{cite journal |vauthors=Isoda N, Eguchi Y, Nukaya H, etal |title=Clinical efficacy of superfine dispersed lentinan (β-1,3-glucan) in patients with hepatocellular carcinoma |journal=Hepatogastroenterology |volume=56 |issue=90 |pages=437–41 |year=2009 |pmid=19579616 }}</ref><ref name="pmid19453066">{{cite journal |vauthors=Shimizu K, Watanabe S, Watanabe S, etal |title=Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer |journal=Hepatogastroenterology |volume=56 |issue=89 |pages=240–4 |year=2009 |pmid=19453066 }}</ref> however, evidence of ] is lacking.<ref name="webmd">{{cite web|title=Lentinan|url=http://www.webmd.com/vitamins-supplements/ingredientmono-763-lentinan.aspx?activeingredientid=763&activeingredientname=lentinan|publisher=]|access-date=June 10, 2017}}</ref><ref name="MSKCC">{{cite web|title=Lentinan|url=https://www.mskcc.org/cancer-care/integrative-medicine/herbs/lentinan|publisher=]|access-date=June 10, 2017}}</ref>


===Adverse effects=== ===Adverse effects===
Lentinan has been reported to cause ].<ref name="Nakamura">{{cite journal|last1=Nakamura|first1=T|title=Shiitake (''Lentinus edodes'') dermatitis|journal=Contact Dermatitis|date=1992|volume=27|issue=2|pages=65–70|pmid=1395630|doi=10.1111/j.1600-0536.1992.tb05211.x|s2cid=7320474|doi-access=free}}</ref> Lentinan has been reported to cause ].<ref name="Nakamura">{{cite journal | vauthors = Nakamura T | title = Shiitake (Lentinus edodes) dermatitis | journal = Contact Dermatitis | volume = 27 | issue = 2 | pages = 65–70 | date = August 1992 | pmid = 1395630 | doi = 10.1111/j.1600-0536.1992.tb05211.x | s2cid = 7320474 | doi-access = free }}</ref>


==See also== == See also ==
*] *]


==References== == References ==
{{Reflist|30em}} {{Reflist|30em}}


Revision as of 18:39, 22 November 2023

Chemical compound Pharmaceutical compound
Lentinan
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass~ 500,000 Da
  (what is this?)  (verify)

Lentinan is a polysaccharide isolated from the fruit body of shiitake mushroom (Lentinula edodes).

Chemistry

Lentinan is a β-1,3 beta-glucan with β-1,6 branching. It has a molecular weight of 500,000 Da and specific rotation of +14-22° (NaOH).

Research

Preclinical studies

An in vitro experiment showed lentinan stimulated production of white blood cells in the human cell line U937. Lentinan is thought to be inactive in humans when given orally and is therefore administered intravenously. The authors of an in vivo study of lentinan suggested that the compound may be active when administered orally in mice.

Human clinical trials

Lentinan has been the subject of a limited number of clinical studies in cancer patients in Japan; however, evidence of efficacy is lacking.

Adverse effects

Lentinan has been reported to cause shiitake mushroom dermatitis.

See also

References

  1. Sia GM, Candlish JK (March 1999). "Effects of shiitake (Lentinus edodes) extract on human neutrophils and the U937 monocytic cell line". Phytotherapy Research. 13 (2): 133–137. doi:10.1002/(SICI)1099-1573(199903)13:2<133::AID-PTR398>3.0.CO;2-O. PMID 10190187.
  2. Ng ML, Yap AT (October 2002). "Inhibition of human colon carcinoma development by lentinan from shiitake mushrooms (Lentinus edodes)". Journal of Alternative and Complementary Medicine. 8 (5): 581–589. doi:10.1089/107555302320825093. PMID 12470439.
  3. Yang P, Liang M, Zhang Y, Shen B (August 2008). "Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC". Advances in Therapy. 25 (8): 787–794. doi:10.1007/s12325-008-0079-x. PMID 18670743. S2CID 33140754.
  4. Nimura H, Mitsumori N, Takahashi N, Kashimura H, Takayama S, Kashiwagi H, Yanaga K (June 2006). "". Gan to Kagaku Ryoho. Cancer & Chemotherapy (in Japanese). 33 Suppl 1 (1): 106–109. PMID 16897983.
  5. Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). "A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group". Hepato-Gastroenterology. 46 (28): 2662–2668. PMID 10522061.
  6. Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J (July 2009). "Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer". Anticancer Research. 29 (7): 2739–2745. PMID 19596954.
  7. Hazama S, Watanabe S, Ohashi M, Yagi M, Suzuki M, Matsuda K, et al. (July 2009). "Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer". Anticancer Research. 29 (7): 2611–2617. PMID 19596936.
  8. Kataoka H, Shimura T, Mizoshita T, Kubota E, Mori Y, Mizushima T, et al. (2009). "Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life". Hepato-Gastroenterology. 56 (90): 547–550. PMID 19579640.
  9. Isoda N, Eguchi Y, Nukaya H, Hosho K, Suga Y, Suga T, et al. (2009). "Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma". Hepato-Gastroenterology. 56 (90): 437–441. PMID 19579616.
  10. Shimizu K, Watanabe S, Watanabe S, Matsuda K, Suga T, Nakazawa S, Shiratori K (2009). "Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer". Hepato-Gastroenterology. 56 (89): 240–244. PMID 19453066.
  11. "Lentinan". WebMD. Retrieved June 10, 2017.
  12. "Lentinan". Memorial Sloan Kettering Cancer Center. Retrieved June 10, 2017.
  13. Nakamura T (August 1992). "Shiitake (Lentinus edodes) dermatitis". Contact Dermatitis. 27 (2): 65–70. doi:10.1111/j.1600-0536.1992.tb05211.x. PMID 1395630. S2CID 7320474.

External links

  • Lentinan effects (antitumor and others)
  • Memorial Sloan-Kettering Cancer Center's page for Lentinan.
Immunostimulants (L03)
Endogenous
Cytokines
Colony-stimulating factors
Interferons
Interleukins
Other protein / peptide
Other
Exogenous
Types of carbohydrates
General
Geometry
Monosaccharides
Dioses
Trioses
Tetroses
Pentoses
Hexoses
Heptoses
Above 7
Multiple
Disaccharides
Trisaccharides
Tetrasaccharides
Other
oligosaccharides
Polysaccharides
Categories:
Lentinan: Difference between revisions Add topic